文献速递其他结缔组织病

利妥昔单抗治疗难治性成人及幼年皮肌炎皮损改善

Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab.
PubMed 文献 · Rheumatology (Oxford) · 2016-11-11

该随机安慰剂相位对照试验纳入难治性成人皮肌炎(n=72)与幼年皮肌炎(n=48)患者,所有受试者均接受利妥昔单抗。结果显示两组皮肤疾病活动度视觉模拟评分均较基线显著改善,成人组由3.22降至1.72(P=0.0002),幼年组由3.26降至1.56(P<0.0001)。

要点

  • 利妥昔单抗加入标准治疗后,成人及幼年皮肌炎难治性皮疹均获改善。
  • 红皮病、无溃疡或坏死继发改变的红斑疹、向阳性皮疹、Gottron征及丘疹改善最显著。
  • 早期使用利妥昔单抗的成人患者皮肤应答(相对基线改善20%)有更快的趋势(P=0.052)。

核心结论

  • 在随机安慰剂相位对照试验中,难治性成人及幼年皮肌炎患者加用利妥昔单抗后皮肤皮疹获得改善。

研究设计与样本

  • 随机安慰剂相位对照试验,难治性成人皮肌炎72例与幼年皮肌炎48例,分早期(第0/1周)与晚期(第8/9周)利妥昔单抗组,所有受试者均接受研究药物,允许稳定联合用药。

主要发现

  • 利妥昔单抗给药后,成人及幼年皮肌炎亚组皮肤疾病活动度从基线至试验结束均显著改善。
  • 成人皮肌炎皮肤视觉模拟评分由3.22降至1.72(P=0.0002),幼年皮肌炎由3.26降至1.56(P<0.0001)。
  • 红皮病、无溃疡或坏死继发改变的红斑疹、向阳性皮疹、Gottron征及丘疹改善最显著。
  • 试验中较早接受利妥昔单抗的成人皮肌炎患者,相比晚期B细胞清除者,皮肤应答(相对基线改善20%)有更快的趋势(P=0.052)。

关键数值与推荐

  • 皮肤疾病活动度采用肌炎疾病活动度评估工具的视觉模拟评分;皮肤损伤采用肌炎损伤指数评估。
  • 分析采用χ2检验、配对t检验与Wilcoxon检验。

临床怎么用

  • 对标准治疗下皮疹难治的成人及幼年皮肌炎,可考虑加用利妥昔单抗以改善皮肤活动度。
  • 评估皮肤改善时可关注红皮病、红斑疹、向阳性皮疹、Gottron征及丘疹等具体皮疹表现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The aim was to assess the efficacy of rituximab for the cutaneous manifestations of adult DM and JDM. METHODS: Patients with refractory adult DM (n = 72) and JDM (n = 48) were treated with rituximab in a randomized placebo-phase-controlled trial [either rituximab early drug (week 0/1) or rituximab late arms (week 8/9), such that all subjects received study drug]. Stable concomitant therapy was allowed. Cutaneous disease activity was assessed using the Myositis Disease Activity Assessment Tool, which grades cutaneous disease activity on a visual analog scale. A myositis damage assessment tool, termed the Myositis Damage Index, was used to assess cutaneous damage. Improvement post-rituximab was evaluated in individual rashes as well as in cutaneous disease activity and damage scores. The χ2 test, Student's paired t-test and Wilcoxon test were used for analysis. RESULTS: There were significant improvements in cutaneous disease activity from baseline to the end of the trial after rituximab administration in both adult DM and JDM subsets. The cutaneous visual analog scale activity improved in adult DM (3.22-1.72, P = 0.0002) and JDM (3.26-1.56, P <0.0001), with erythroderma, erythematous rashes without secondary changes of ulceration or necrosis, heliotrope, Gottron sign and papules improving most significantly. Adult DM subjects receiving rituximab earlier in the trial demonstrated a trend for faster cutaneous response (20% relative improvement from baseline) compared with those receiving B cell depletion later (P = 0.052). CONCLUSION: Refractory skin rashes in adult DM and JDM showed improvement after the addition of rituximab to the standard therapy in a clinical trial.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Aggarwal R, Loganathan P, Koontz D, et al. Cutaneous improvement in refractory adult and juvenile dermatomyositis after treatment with rituximab. Rheumatology (Oxford). 2016. PMID: 27837048. doi:10.1093/rheumatology/kew396

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。